Molecular Staging Individualizing Cancer Management

J Surg Oncol. 2012 Apr 1;105(5):468-74. doi: 10.1002/jso.21858.

Abstract

Although the most important prognostic and predictive marker in colorectal cancer is tumor cells in lymph nodes, approximately 30% of patients who are node-negative die from occult metastases. Molecular staging employing specific markers and sensitive detection technologies has emerged as a powerful platform to assess prognosis in node-negative colon cancer. Integrating molecular staging into algorithms that individualize patient management will require validation and the definition of relationships between occult tumor cells, prognosis, and responses to chemotherapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers, Tumor / genetics*
  • Colonic Neoplasms / diagnosis*
  • Colonic Neoplasms / genetics*
  • Colonic Neoplasms / pathology
  • Colonic Neoplasms / therapy
  • Humans
  • Lymph Nodes / pathology*
  • Lymphatic Metastasis
  • Neoplasm Staging
  • Neoplasms / diagnosis
  • Neoplasms / genetics
  • Predictive Value of Tests
  • Prognosis
  • Receptors, Enterotoxin
  • Receptors, Guanylate Cyclase-Coupled / genetics*
  • Receptors, Peptide / genetics*
  • Reverse Transcriptase Polymerase Chain Reaction* / economics
  • Risk Assessment
  • Risk Factors
  • United States

Substances

  • Biomarkers, Tumor
  • Receptors, Peptide
  • Receptors, Enterotoxin
  • Receptors, Guanylate Cyclase-Coupled